SG11201901460UA - Method for producing the crystalline form of modification a of calcobutrol - Google Patents
Method for producing the crystalline form of modification a of calcobutrolInfo
- Publication number
- SG11201901460UA SG11201901460UA SG11201901460UA SG11201901460UA SG11201901460UA SG 11201901460U A SG11201901460U A SG 11201901460UA SG 11201901460U A SG11201901460U A SG 11201901460UA SG 11201901460U A SG11201901460U A SG 11201901460UA SG 11201901460U A SG11201901460U A SG 11201901460UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- modification
- crystalline form
- pct
- str
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic System
- C07F3/04—Calcium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
WO 18/05 99 14 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 05 April 2018 (05.04.2018) WIP0 I PCT °million °nolo ommonoin turnoff ois (10) International Publication Number WO 2018/059914 Al (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, C07D 257/02 (2006.01) A61K 49/10 (2006.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/EP2017/072683 Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a (22) International Filing Date: patent (Rule 4.1700) 11 September 2017 (11.09.2017) Published: (25) Filing Language: English — with international search report (Art. 21(3)) (26) Publication Language: English (30) Priority Data: 16190812.4 27 September 2016 (27.09.2016) EP (71) Applicant: BAYER PHARMA AKTIENGESEL- LSCHAFT [DE/DE]; Miillerstr. 178, 13353 Berlin (DE). (72) Inventors: PLATZEK, Johannes; Grottkauer Str. 55, 12621 Berlin (DE). TRENTMANN, Wilhelm; Gassel- stiege 419, 48159 Miinster (DE). (74) Agent: BIP PATENTS; Alfred-Nobel-Str. 10, 40789 Mon- heim am Rhein NRW (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: METHOD FOR PRODUCING THE CRYSTALLINE FORM OF MODIFICATION A OF CALCOBUTROL (57) : A method is described for production of a high purity compound of 0 the formula (I) in crystalline form of the modification A. In this, starting from high H 0 0 purity gadobutrol, the gadolinium is removed by decomplexation with oxalic acid, and >/ \ /--\ / ‘ then with a calcium salt the calcium complex is produced in high purity. During the O N N 0 crystallization, a water equivalent of 9-11 weight % is set. The crystalline form of C Ca 2+ D the modification A of the compound of the formula (I) is used in the production of 0 N N 0 H Gadovist. / HO HO
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16190812 | 2016-09-27 | ||
| PCT/EP2017/072683 WO2018059914A1 (en) | 2016-09-27 | 2017-09-11 | Method for producing the crystalline form of modification a of calcobutrol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901460UA true SG11201901460UA (en) | 2019-03-28 |
Family
ID=57003447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901460UA SG11201901460UA (en) | 2016-09-27 | 2017-09-11 | Method for producing the crystalline form of modification a of calcobutrol |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10793532B2 (en) |
| EP (1) | EP3519394B1 (en) |
| JP (2) | JP7053590B2 (en) |
| KR (1) | KR102395523B1 (en) |
| CN (1) | CN109803958B (en) |
| AR (1) | AR109729A1 (en) |
| AU (1) | AU2017333698B2 (en) |
| BR (1) | BR112019006066A2 (en) |
| CA (1) | CA3038036C (en) |
| CY (1) | CY1123317T1 (en) |
| DK (1) | DK3519394T3 (en) |
| ES (1) | ES2809736T3 (en) |
| HR (1) | HRP20200922T1 (en) |
| HU (1) | HUE050553T2 (en) |
| IL (1) | IL265536B (en) |
| LT (1) | LT3519394T (en) |
| MX (1) | MX2019003540A (en) |
| NZ (1) | NZ751256A (en) |
| PL (1) | PL3519394T3 (en) |
| PT (1) | PT3519394T (en) |
| RS (1) | RS60392B1 (en) |
| SG (1) | SG11201901460UA (en) |
| SI (1) | SI3519394T1 (en) |
| TW (1) | TWI765913B (en) |
| UY (1) | UY37421A (en) |
| WO (1) | WO2018059914A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3519394T1 (en) * | 2016-09-27 | 2020-08-31 | Bayer Pharma Aktiengesellschaft | Method for producing the crystalline form of modification a of calcobutrol |
| EP3870569A4 (en) * | 2018-10-24 | 2022-08-24 | Biophore India Pharmaceuticals Pvt. Ltd. | Novel process for the preparation of macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetra azacyclododecane-1,4,7-triyl) triacetic acid and it's complexes with paramagnetic metal ions |
| CN111039885B (en) * | 2019-12-06 | 2021-03-05 | 广州康瑞泰药业有限公司 | Method for preparing high-purity combretastatin |
| KR20210112910A (en) * | 2020-03-06 | 2021-09-15 | 주식회사 엔지켐생명과학 | Method for manufacturing calcobutrol to gadovist excipient |
| KR20210114742A (en) * | 2020-03-11 | 2021-09-24 | 주식회사 엔지켐생명과학 | Method for manufacturing calteridol |
| CN114573522A (en) * | 2020-11-30 | 2022-06-03 | 江苏恒瑞医药股份有限公司 | Novel crystal form of combretastatin calcium and preparation method thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1491129A (en) | 1975-06-04 | 1977-11-09 | Guerbet Sa | Iodo-benzene derivatives and an x-ray contrast medium containing them |
| US4284620A (en) | 1979-03-23 | 1981-08-18 | Mallinckrodt, Inc. | N-(2-Hydroxyethyl)-2,4,6-triiodo-3,5-bis-(2-keto-L-gulonamido)benzamide and radiological compositions containing same |
| NO161560C (en) | 1980-04-17 | 1989-09-06 | Univ California | SYMMETRIC TRYODISOFTALDIAMIDE DERIVATIVES AND ROENTGENCONTRACTORS CONTAINING THESE. |
| DE3150916A1 (en) | 1981-12-18 | 1983-06-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | N-HYDROXYAETHYLATED 2,4,6-TRIJODAMINOISIOPHTHALIC ACID-BISTRIHYDROXYBUTYLAMIDES, THEIR PRODUCTION AND THEIR CONTAINING X-RAY CONTRASTING AGENTS " |
| US5064633A (en) | 1984-06-04 | 1991-11-12 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes, their formulations and use |
| US5059412A (en) | 1984-06-04 | 1991-10-22 | The Dow Chemical Company | Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors |
| MX174467B (en) | 1986-01-23 | 1994-05-17 | Squibb & Sons Inc | 1,4,7-TRISCARBOXIMETHYL-1,4,7,10-TETRAAZACICLODO DECAN SUBSTITUTE IN 1 AND ANALOG COMPOUNDS |
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| DE3625417C2 (en) | 1986-07-28 | 1998-10-08 | Schering Ag | Tetraazacyclododecane derivatives |
| DE3640708C2 (en) | 1986-11-28 | 1995-05-18 | Schering Ag | Improved pharmaceuticals containing metals |
| DE4009119A1 (en) | 1990-03-19 | 1991-09-26 | Schering Ag | 1,4,7,10-TETRAAZACYCLODODECANE-BUTYLTRIOLS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM |
| PT97124A (en) | 1990-03-23 | 1991-12-31 | Gist Brocades Nv | PROCESS FOR THE PREPARATION OF INTERLEUCIN-6 INHIBITOR COMPOSITIONS (IL-6) |
| DE4035760A1 (en) | 1990-11-08 | 1992-05-14 | Schering Ag | MONO-N-SUBSTITUTED 1,4,7,10-TETRAAZACYCLODODECAN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM |
| DE4237943C2 (en) | 1992-11-06 | 1997-10-23 | Schering Ag | Process for the preparation of metal complexes of N-beta-hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecane and N-beta-hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecane Derivatives |
| US5410043A (en) | 1991-12-06 | 1995-04-25 | Schering Aktiengesellschaft | Process for the production of mono-N-substituted tetraaza macrocycles |
| DE4218744C2 (en) | 1992-06-04 | 1997-11-06 | Schering Ag | Process for the preparation of N-β-hydroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecane and N-β-hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecane derivatives and their metal complexes |
| DE4318369C1 (en) | 1993-05-28 | 1995-02-09 | Schering Ag | Use of macrocyclic metal complexes as temperature probes |
| US5358704A (en) | 1993-09-30 | 1994-10-25 | Bristol-Myers Squibb | Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents |
| IT1275426B (en) | 1995-05-16 | 1997-08-07 | Bracco Spa | RECOVERY OF THE GADOLINIUM AND ITS COMPLEX AGENTS FROM AQUEOUS SOLUTIONS CONTAINING THEIR COMPLEXES |
| DE19724186C2 (en) | 1997-06-02 | 2002-07-18 | Schering Ag | Process for the mono- and 1,7-bis-N-ß-hydroxyalkylation of cycles and the corresponding N-ß-hydroxyalkyl-1,4,7,10-tetraazacyclododecane-Li salt complexes |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| DE102009053171B4 (en) * | 2009-11-04 | 2011-07-21 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Process for the preparation of the calcium complex of dihydroxy-hydroxy-methylpropyl-tetraazacyclododecane-triacetic acid (Calcobutrol) |
| DK2896405T3 (en) * | 2011-04-21 | 2020-04-06 | Bayer Ip Gmbh | Preparation of high purity gadobutrol |
| US10463611B2 (en) * | 2011-06-08 | 2019-11-05 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
| KR101693400B1 (en) * | 2014-09-17 | 2017-01-05 | 에스티팜 주식회사 | A Method for Preparing Calcobutrol |
| CN105037288B (en) * | 2015-07-23 | 2017-11-03 | 上海现代制药海门有限公司 | A kind of preparation method of cloth alcohol |
| CN106187930B (en) * | 2016-07-12 | 2018-10-19 | 嘉实（湖南）医药科技有限公司 | The preparation method of high-purity calcobutrol |
| SI3519394T1 (en) * | 2016-09-27 | 2020-08-31 | Bayer Pharma Aktiengesellschaft | Method for producing the crystalline form of modification a of calcobutrol |
-
2017
- 2017-09-11 SI SI201730298T patent/SI3519394T1/en unknown
- 2017-09-11 EP EP17768733.2A patent/EP3519394B1/en active Active
- 2017-09-11 HU HUE17768733A patent/HUE050553T2/en unknown
- 2017-09-11 RS RS20200654A patent/RS60392B1/en unknown
- 2017-09-11 PL PL17768733T patent/PL3519394T3/en unknown
- 2017-09-11 MX MX2019003540A patent/MX2019003540A/en unknown
- 2017-09-11 PT PT177687332T patent/PT3519394T/en unknown
- 2017-09-11 DK DK17768733.2T patent/DK3519394T3/en active
- 2017-09-11 ES ES17768733T patent/ES2809736T3/en active Active
- 2017-09-11 IL IL265536A patent/IL265536B/en unknown
- 2017-09-11 SG SG11201901460UA patent/SG11201901460UA/en unknown
- 2017-09-11 LT LTEP17768733.2T patent/LT3519394T/en unknown
- 2017-09-11 WO PCT/EP2017/072683 patent/WO2018059914A1/en active Application Filing
- 2017-09-11 US US16/336,217 patent/US10793532B2/en active Active
- 2017-09-11 CN CN201780058632.5A patent/CN109803958B/en active Active
- 2017-09-11 CA CA3038036A patent/CA3038036C/en active Active
- 2017-09-11 KR KR1020197008763A patent/KR102395523B1/en active IP Right Grant
- 2017-09-11 NZ NZ751256A patent/NZ751256A/en unknown
- 2017-09-11 JP JP2019516489A patent/JP7053590B2/en active Active
- 2017-09-11 BR BR112019006066A patent/BR112019006066A2/en not_active Application Discontinuation
- 2017-09-11 AU AU2017333698A patent/AU2017333698B2/en active Active
- 2017-09-27 UY UY0001037421A patent/UY37421A/en unknown
- 2017-09-27 TW TW106133043A patent/TWI765913B/en active
- 2017-09-27 AR ARP170102671A patent/AR109729A1/en unknown
-
2020
- 2020-06-09 HR HRP20200922TT patent/HRP20200922T1/en unknown
- 2020-07-30 CY CY20201100709T patent/CY1123317T1/en unknown
- 2020-09-22 US US17/028,467 patent/US11390592B2/en active Active
-
2022
- 2022-03-03 JP JP2022032582A patent/JP7444914B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901460UA (en) | Method for producing the crystalline form of modification a of calcobutrol | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| SG11201810683VA (en) | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | |
| SG11201809132RA (en) | Novel compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201805595TA (en) | Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201909615YA (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| SG11201807540UA (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201804587QA (en) | Isoindole compounds |